Arena Pharmaceuticals, Inc. Interest Paid, Excluding Capitalized Interest, Operating Activities
Arena Pharmaceuticals, Inc. reported Interest Paid, Excluding Capitalized Interest, Operating Activities of $4.08 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-23.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:InterestPaidNet · last filed 2022-02-23
- Arena Pharmaceuticals, Inc. interest paid, excluding capitalized interest, operating activities for the quarter ending 2021-12-31 was $981.00K, a 9.25% decline year-over-year.
- Arena Pharmaceuticals, Inc. interest paid, excluding capitalized interest, operating activities for the quarter ending 2021-09-30 was $1.01M, a 8.88% decline year-over-year.
- Arena Pharmaceuticals, Inc. interest paid, excluding capitalized interest, operating activities for the quarter ending 2021-06-30 was $1.03M, a 8.26% decline year-over-year.
- Arena Pharmaceuticals, Inc. interest paid, excluding capitalized interest, operating activities for the quarter ending 2021-03-31 was $1.06M, a 7.85% decline year-over-year.
- Arena Pharmaceuticals, Inc. interest paid, excluding capitalized interest, operating activities for fiscal 2021 was $4.08M, a 8.55% decline from fiscal 2020.
- Arena Pharmaceuticals, Inc. interest paid, excluding capitalized interest, operating activities for fiscal 2020 was $4.46M, a 6.87% decline from fiscal 2019.
- Arena Pharmaceuticals, Inc. interest paid, excluding capitalized interest, operating activities for fiscal 2019 was $4.79M, a 15.96% decline from fiscal 2018.
- Arena Pharmaceuticals, Inc. interest paid, excluding capitalized interest, operating activities for fiscal 2018 was $5.70M, a 4.54% decline from fiscal 2017.
| Period end | Interest Paid, Excluding Capitalized Interest, Operating Activities 3 month | Interest Paid, Excluding Capitalized Interest, Operating Activities 6 month | Interest Paid, Excluding Capitalized Interest, Operating Activities 9 month | Interest Paid, Excluding Capitalized Interest, Operating Activities 12 month |
|---|---|---|---|---|
| 2021-12-31 | $981.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $1.99M derived: sum of 2 quarters · filed 2022-02-23 | $3.02M derived: sum of 3 quarters · filed 2022-02-23 | $4.08M 10-K · filed 2022-02-23 |
| 2021-09-30 | $1.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $2.04M derived: sum of 2 quarters · filed 2021-11-04 | $3.10M 10-Q · filed 2021-11-04 | $4.18M derived: sum of 4 quarters · filed 2022-02-23 |
| 2021-06-30 | $1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $2.09M 10-Q · filed 2021-08-05 | $3.17M derived: sum of 3 quarters · filed 2022-02-23 | $4.28M derived: sum of 4 quarters · filed 2022-02-23 |
| 2021-03-31 | $1.06M 10-Q · filed 2021-05-05 | $2.14M derived: sum of 2 quarters · filed 2022-02-23 | $3.24M derived: sum of 3 quarters · filed 2022-02-23 | $4.37M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $2.19M derived: sum of 2 quarters · filed 2022-02-23 | $3.31M derived: sum of 3 quarters · filed 2022-02-23 | $4.46M 10-K · filed 2022-02-23 |
| 2020-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $2.23M derived: sum of 2 quarters · filed 2021-11-04 | $3.38M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $1.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $2.27M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $1.15M 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | $4.79M 10-K · filed 2022-02-23 | |||
| 2018-12-31 | $5.70M 10-K · filed 2021-02-23 | |||
| 2017-12-31 | $5.97M 10-K · filed 2020-02-27 | |||
| 2016-12-31 | $6.30M 10-K · filed 2019-02-28 | |||
| 2015-12-31 | $6.56M 10-K · filed 2018-03-14 | |||
| 2014-12-31 | $6.78M 10-K · filed 2017-03-15 | |||
| 2013-12-31 | $6.95M 10-K · filed 2016-02-29 | |||
| 2012-12-31 | $7.67M 10-K · filed 2015-03-02 | |||
| 2011-12-31 | $9.49M 10-K · filed 2014-03-03 | |||
| 2010-12-31 | $13.43M 10-K · filed 2013-03-01 | |||
| 2009-12-31 | $10.30M 10-K · filed 2012-03-15 |